Vaccine biotechnology company Novavax (NASDAQ:NVAX) in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close ...
Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results